Our study demonstrated that the HDAC6 inhibitor ricolinostat is effective in reducing lymphoma cell growth and increasing apoptosis as a single agent and the efficacy is increased by the combination with bendamustine. This evidence concerns the gene HDAC6 and lymphoma.